Get Your Personalized Supplement StackSupplement Stack Quiz

Lactobacillus breve

Q: Is Lactobacillus breve safe for long-term use?

Yes, Lactobacillus breve is generally considered safe for long-term use in healthy individuals, with no significant adverse effects reported in extended studies.

Q: Can it be taken with antibiotics?

Yes, it is often recommended to take L. breve during and after antibiotic therapy to help prevent antibiotic-associated diarrhea.

Q: How soon can benefits be expected?

Benefits, particularly in diarrhea prevention or reduction, typically become noticeable within a few days to a few weeks of consistent use.

Q: Does it work for all types of diarrhea?

Most evidence supports its use for antibiotic-associated and infectious diarrhea; its efficacy for other types of diarrhea is less robustly supported by research.

Q: Is strain specificity important?

Yes, probiotic effects are highly strain-specific. The benefits observed with L. breve may not apply to other Lactobacillus strains, emphasizing the importance of specific strain research.

Also known as: L. breve, Lactobacillus breve

Overview

Lactobacillus breve is a Gram-positive, facultative anaerobic bacterium commonly found in the human gastrointestinal tract and fermented dairy products. As a species within the Lactobacillus genus, it is widely utilized as a probiotic supplement, primarily to support digestive health and modulate the gut microbiota. Its key applications include preventing and treating various forms of diarrhea, such as antibiotic-associated diarrhea (AAD) and infectious diarrhea, and potentially enhancing immune function. L. breve is characterized by its resilience, surviving gastric acidity and bile salts, and its ability to adhere to intestinal mucosa. It produces lactic acid, which contributes to an acidic gut environment, thereby inhibiting the growth of pathogenic bacteria. While research on L. breve is ongoing, with several randomized controlled trials and some meta-analyses available, its evidence base is considered moderate compared to more extensively studied probiotic strains.

Benefits

Lactobacillus breve offers several evidence-based benefits, primarily in gastrointestinal health. Its most significant effect is the prevention and reduction of antibiotic-associated diarrhea (AAD) and infectious diarrhea in both children and adults. Studies indicate a potential reduction in the duration and severity of diarrheal episodes. While specific effect sizes for L. breve alone are less quantified, meta-analyses on Lactobacillus species suggest a relative risk reduction in diarrhea incidence by approximately 20-30% when probiotics are used. Secondary benefits include the modulation of immune responses, potentially reducing inflammation within the gut, and supporting the management of symptoms associated with irritable bowel syndrome (IBS) and other gastrointestinal disorders. These benefits are particularly relevant for individuals undergoing antibiotic treatment and may also contribute to healthy gut microbiota development in infants. Benefits typically manifest within days to weeks of consistent administration.

How it works

Lactobacillus breve exerts its beneficial effects primarily within the gastrointestinal tract through several key mechanisms. It produces lactic acid, which lowers the gut's pH, creating an unfavorable environment for the growth of many pathogenic bacteria. This bacterium also engages in competitive adhesion to the intestinal mucosa, physically preventing harmful pathogens from colonizing the gut lining. Furthermore, L. breve modulates host immune responses, enhancing mucosal immunity and potentially reducing inflammation. As a live microorganism, it is not absorbed systemically but rather exerts its local effects by influencing the composition of the gut microbiota and strengthening the intestinal barrier function. While specific molecular targets are not fully elucidated, its actions involve direct interactions with epithelial cells and immune cells present in the gut mucosa.

Side effects

Lactobacillus breve is generally regarded as safe (GRAS) and has a long history of safe use in foods and supplements. The most common side effects, occurring in more than 5% of individuals, are mild gastrointestinal symptoms such as bloating or gas. Uncommon side effects (1-5%) may include rare allergic reactions or intolerance. Very rare cases (<1%) of bacteremia or sepsis have been reported, primarily in severely immunocompromised patients, highlighting the importance of caution in this population. There are no significant known drug interactions; however, individuals taking immunosuppressants should exercise caution and consult a healthcare provider. Contraindications include severely immunocompromised individuals or those with severe underlying illnesses, who should seek medical advice before use. While generally considered safe for children and pregnant women, clinical guidance is recommended for these special populations.

Dosage

The typical effective dosage for Lactobacillus breve ranges from 1 billion to 10 billion CFU (colony-forming units) per day in clinical studies. For therapeutic effects, an optimal dosage of 5–10 billion CFU daily is commonly recommended. There is no established maximum safe dose, with trials safely using doses up to 20 billion CFU daily. Timing considerations are important, especially when used for diarrhea prevention; it is often administered during or shortly after antibiotic treatment. L. breve is available in various forms, including capsules, powders, and fermented dairy products, and its viability and storage conditions are crucial for efficacy. Survival through gastric acid and bile is critical for its action, and enteric-coated formulations may improve delivery to the intestines. The efficacy of L. breve can be enhanced by cofactors such as prebiotics like fructooligosaccharides (FOS), which may promote its colonization in the gut.

FAQs

Is Lactobacillus breve safe for long-term use?

Yes, Lactobacillus breve is generally considered safe for long-term use in healthy individuals, with no significant adverse effects reported in extended studies.

Can it be taken with antibiotics?

Yes, it is often recommended to take L. breve during and after antibiotic therapy to help prevent antibiotic-associated diarrhea.

How soon can benefits be expected?

Benefits, particularly in diarrhea prevention or reduction, typically become noticeable within a few days to a few weeks of consistent use.

Does it work for all types of diarrhea?

Most evidence supports its use for antibiotic-associated and infectious diarrhea; its efficacy for other types of diarrhea is less robustly supported by research.

Is strain specificity important?

Yes, probiotic effects are highly strain-specific. The benefits observed with L. breve may not apply to other Lactobacillus strains, emphasizing the importance of specific strain research.

Research Sources

https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2022.983075/full – This systematic review and meta-analysis on Lactobacillus species, though not exclusively on L. breve, found that probiotics, including various Lactobacillus strains, significantly reduce the incidence of diarrhea compared to placebo. The study emphasized the importance of strain-specific effects and acknowledged limitations due to heterogeneity in probiotic formulations and a lack of studies focusing solely on L. breve. It employed high-quality meta-analytic methods, including publication bias assessment.
https://pubmed.ncbi.nlm.nih.gov/38064222/ – This expert consensus and literature review highlights the critical need for strain-specific analysis in probiotic research and systematic reviews. It underscores that evaluating individual probiotic strains, such as L. breve, separately from others is essential for improving clinical decision-making and accurately assessing efficacy. The findings support the importance of targeted research to understand the unique effects of each probiotic strain.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2018.00124/full – This meta-analysis of randomized controlled trials on Lactobacillus strains for antibiotic-associated diarrhea demonstrated a significant reduction in both the duration and incidence of diarrhea with specific Lactobacillus strains. While it included various strains, it noted limited RCTs specifically for L. breve and called for more targeted research on individual strains. The study utilized a rigorous meta-analytic approach, including subgroup analyses, to assess strain-specific efficacy.